U.S. government gave $3.7 million grant to Wuhan lab at cent

Re: U.S. government gave $3.7 million grant to Wuhan lab at

Postby admin » Tue Feb 09, 2021 12:49 am

Covid: South Africa halts AstraZeneca vaccine rollout over new variant
by bbc.com
February 8, 2021

NOTICE: THIS WORK MAY BE PROTECTED BY COPYRIGHT

YOU ARE REQUIRED TO READ THE COPYRIGHT NOTICE AT THIS LINK BEFORE YOU READ THE FOLLOWING WORK, THAT IS AVAILABLE SOLELY FOR PRIVATE STUDY, SCHOLARSHIP OR RESEARCH PURSUANT TO 17 U.S.C. SECTION 107 AND 108. IN THE EVENT THAT THE LIBRARY DETERMINES THAT UNLAWFUL COPYING OF THIS WORK HAS OCCURRED, THE LIBRARY HAS THE RIGHT TO BLOCK THE I.P. ADDRESS AT WHICH THE UNLAWFUL COPYING APPEARED TO HAVE OCCURRED. THANK YOU FOR RESPECTING THE RIGHTS OF COPYRIGHT OWNERS.


South Africa has put its rollout of the Oxford-AstraZeneca vaccine on hold after a study showed "disappointing" results against its new Covid variant.

Scientists say the variant accounts for 90% of new Covid cases in South Africa.

The trial, involving some 2,000 people, found that the vaccine offered "minimal protection" against mild and moderate cases.

But experts are hopeful that the vaccine will still be effective at preventing severe cases.

South Africa has recorded almost 1.5 million coronavirus cases and more than 46,000 deaths since the pandemic began - a higher toll than any other country on the continent.

The country has received one million doses of the Oxford-AstraZeneca jab and was preparing to start vaccinating people.

On Monday, the World Health Organization (WHO) warned against jumping to conclusions about the efficacy of Covid vaccines.

Dr Katherine O'Brien, the WHO's director of immunisation, said it was very plausible that the Oxford-AstraZeneca vaccine would still have a meaningful impact on the South African variant, especially when it came to preventing hospitalisations and death.

"Comparing from one piece of evidence to the next really can't be done without a sort of level playing field," she said, referring to the evaluation of different trials in different populations and age groups.

Dr O'Brien stressed that the WHO's expert panel held "a very positive view" of proceeding with the use of the vaccine, including in areas where variants were circulating, but that more data and information would be needed as the pandemic continued.

South Africa's Health Minister Zweli Mkhize said his government would wait for further advice on how best to proceed with the AstraZeneca vaccine in light of the findings.

In the meantime, he said, the government would offer vaccines produced by Johnson & Johnson and Pfizer in the coming weeks.

What does it mean for serious cases?

The trial was carried out by researchers at the University of the Witwatersrand in South Africa and the UK's Oxford University, but has not yet been peer reviewed.

The trial's chief investigator, Prof Shabir Madhi, said it showed that "unfortunately, the AstraZeneca vaccine does not work against mild and moderate illness".

Prof Madhi said the study had not been able to investigate the vaccine's efficacy in preventing more serious infections, as participants had an average age of 31 and so did not represent the demographic most at risk of severe symptoms from the virus.

The vaccine's similarity to one produced by Johnson & Johnson, which was found in a recent study to be highly effective at preventing severe disease in South Africa, suggested it would still prevent serious illness, according to Prof Madhi.

"There's still some hope that the AstraZeneca vaccine might well perform as well as the Johnson & Johnson vaccine in a different age group demographic that I address of severe disease," he told the BBC.

Other experts were also hopeful that the vaccine remained effective at combating more serious cases.

"What we're seeing from other vaccine developers is that they have a reduction in efficacy against some of the variant viruses and what that is looking like is that we may not be reducing the total number of cases, but there's still protection in that case against deaths, hospitalisations and severe disease," Prof Sarah Gilbert, Oxford's lead vaccine developer, told the Andrew Marr Show on Sunday.

She said developers were likely to have a modified version of the injection against the South Africa variant, also known as 501.V2 or B.1.351, later this year.

Ministers in the UK have sought to reassure the public over the effectiveness of the Oxford-AstraZeneca vaccine. Vaccines Minister Nadhim Zahawi said the injection appeared to work well against dominant variants in the UK, while Health Minister Edward Argar said there was "no evidence" the vaccine was not effective at preventing severe illness.

Image
How some of the Covid-19 vaccines compare. Source: UK government, Reuters

We should be careful about rushing to judgement
Analysis by Nick Triggle, health correspondent

Viruses mutate - so what is happening is not surprising.

The mutations seen in South Africa change the part of the virus that the vaccines target. It means all the vaccines that have been produced so far are likely to be affected in some way.

Trials for Novavax and Janssen vaccines that were carried out in South Africa showed less effectiveness against this variant. Both are currently before the UK regulator.

Therefore the news about Oxford-AstraZeneca does not come out of the blue.

The fact it now only has "minimal" effect according to reports is concerning - the other vaccines showed effectiveness in the region of 60% against the South African variant.

But we should be careful about rushing to judgement. The study was small so there is only limited confidence in the findings.

What is more, there is still hope the vaccine will prevent serious illness and hospitalisation.

What this once again illustrates is the pandemic is not going to end with one Big Bang. Vaccines are likely to have to change to keep pace with the virus.

Progress will be incremental. But vaccines are still the way out of this.

What do we know about the variant?

The South Africa variant carries a mutation that appears to make it more contagious or easy to spread.

However, there is no evidence that it causes more serious illness for the vast majority of people who become infected. As with the original version, the risk is highest for people who are elderly or have significant underlying health conditions.

At least 20 other countries including Austria, Norway and Japan, have found cases of the variant.

Health officials say all is not lost
Analysis by Pumza Fihlani, southern Africa reporter

Many South Africans have reacted with shock and disappointment at news that the 1.5 million doses of the Oxford/AstraZeneca vaccines will not be as effective as experts had hoped against the new variant first discovered here in November.

While there are now more questions than ready answers, the message from health officials is that all is not lost. They believe the vaccine may still be effective in preventing severe illness and go some way in reducing the number of people who need to be admitted into hospital for treatment.

This is important in a country where some 80% of the population cannot afford private health care and rely on state hospitals - which are currently overstretched - for health care.

So what's the plan now? South Africa's health minister has said they will take a steer from local scientists on how to repurpose the vaccine to get the most out of it.

It has been suggested that the vaccine may be useful if given to the older population and to people with co-morbidities.

In terms of managing people's concerns, the government and scientists may need to go the extra mile in reassuring citizens that there is still a plan in place and lives can and will be saved.
admin
Site Admin
 
Posts: 36180
Joined: Thu Aug 01, 2013 5:21 am

Re: U.S. government gave $3.7 million grant to Wuhan lab at

Postby admin » Fri Mar 19, 2021 10:42 am

How For-Profit Health Care Worsened the Pandemic: Hundreds of Thousands of Deaths and Millions of Infections Would Likely Have Been Prevented Under Medicare for All
by Public Citizen
March 16, 2021
https://www.citizen.org/article/unprepa ... 6f6806d861

WASHINGTON, D.C. – A new white paper by Public Citizen lays out how the for-profit health care system left the U.S. vulnerable and unprepared for the COVID-19 pandemic, and how a single-payer, government-run health care system in which all Americans were covered would have helped the U.S. response to the crisis and prevented thousands of deaths.

“The pandemic has shown how wide the gaps in our health care system remain and how easy it is for families to fall through them. Too many Americans were already suffering unnecessarily prior to the pandemic and COVID-19 just exacerbated the challenges people face,” said Eagan Kemp, Public Citizen’s health care policy advocate. “We already spend far more than any comparably wealthy country on health care while achieving far less and were left wholly unprepared for the COVID-19 pandemic.”

The U.S. remains the only one of the 25 wealthiest countries to not provide universal health care, and the health care system’s focus on profits and not health has cost Americans their lives. Despite having less than 5% of the world’s population, the U.S. has had 25% of the world’s confirmed cases and 20% of the deaths. Public Citizen’s new report demonstrates how:

• Before the pandemic, approximately 87 million Americans were uninsured or underinsured. About one-third of COVID-19 deaths and 40% of infections were tied to a lack of insurance;
• About half of Americans receive their health care through their employer. With more than 22 million Americans losing their job during the pandemic, millions have lost their health insurance;
• Racial health disparities, including access to care, have led to disproportionate deaths in communities of color;
• We have the highest rate of unmet need of any comparably wealthy country, with one-third of Americans reporting that they or a family member has avoided going to the doctor when sick or injured in the past year due to cost;
• Americans are significantly more likely to die of chronic respiratory disease, cardiovascular disease, diabetes or cancer than people in comparably wealthy countries with universal health care systems; and
• A lack of essential funding led to insufficient hospital capacity. The U.S. had only around half the hospital beds per capita of peer nations and far fewer than countries like Japan or Germany.

Thousands of deaths would have been avoided if Medicare for All had been in place prior to the COVID-19 crisis, highlighting the need to enact policy before the next pandemic hits. Under such a system:

• Hospitals, particularly rural hospitals, would receive the funds they need to stay open via yearly budgets instead of relying on admission rates and elective procedures;
• Providers would better be able to coordinate patient care;
• No American would have to skip a doctor visit because of cost or a lack of insurance; and
• People of color would no longer face disproportionately high rates of uninsurance, reducing an important contributor to racial disparities in access to health care.

“We need to be prepared for the next pandemic, and we can’t be under the current for-profit system. The time has come for a health care system that guarantees health care for everyone in the U.S.,” said Kemp. “The time has come for Medicare for All.”

***

Unprepared for COVID-19: How the Pandemic Makes the Case for Medicare for All
by Eagan Kemp
March 16, 2021

Introduction

The COVID-19 crisis should be a sobering wake up call for the American health care system. Despite having less than 5% of the world’s population, the U.S. has had 25% of the world’s confirmed cases and 20% of the deaths.[1] Of the 25 wealthiest countries in the world, the United States remains the only one that does not provide universal health care.[2] Many factors hindered the U.S. response – including failed federal leadership and willful disinformation from a variety of sources – but the reality is that our for-profit health care system put the U.S. at a dangerous disadvantage and hindered rapid response at every turn. It has also meant millions of Americans have contracted COVID-19 unnecessarily and hundreds of thousands of deaths could have been prevented.[3]

Further, the global pandemic has highlighted huge gaps in the foundation of the U.S. health care system. While a full accounting is beyond the scope of this report, six areas particularly highlight just how much our health care system has failed to prepare for and respond to the COVID-19 crisis. Our health care system has been failing Americans for decades and its weaknesses were particularly susceptible to the challenges posed by the COVID-19 pandemic. This report explores the system’s focus on generating profit and revenue for wealthy corporations instead of health and wellbeing for the American people in a number of ways: 1) private insurers profiting by limiting access to care; 2) millions losing their insurance when they lost their jobs during the pandemic; 3) hospitals focusing on profit and revenue over patient wellbeing; 4) many nursing homes failing to meet patients’ needs; 5) our public health preparedness system lacking adequate funding; and 6) the massive health disparities experienced across the U.S., including the particularly devastating effects on communities of color. All of these issues, and many more, would have been significantly improved if a single-payer Medicare for All system had been in place prior to the COVID-19 crisis, highlighting the need to enact Medicare for All before the next pandemic hits.[4]

For-Profit Health Care Left the U.S. Unprepared for COVID-19

The cardinal sin of our health care system is that it puts profits over people and corporations over communities. While examples abound, insurers, hospitals and nursing homes highlight how the motive to generate profit and revenue in our health care system distorts incentives and has hurt Americans in numerous ways before and during the COVID-19 crisis.

Private Insurance System Hindered Access to Care

At the start of the COVID-19 pandemic, approximately 87 million Americans were uninsured or underinsured.[5] While this placed the health of millions of Americans at risk in normal times, the risks are even higher during a pandemic. A recent study found that one-third of COVID-19 deaths and around 40% of infections were linked to a lack of health insurance.[6] For every 10% increase in a county’s uninsured rate, the researchers found a 70% increase in COVID-19 infections and nearly a 50% increase in deaths from COVID-19.[7]

The COVID-19 pandemic showed just how greedy private insurers are, as they were reporting record profits because they were paying out far less in claims due to millions of Americans delaying care.[8] This disparity highlights just how little value insurers are bringing to the health care system despite how much they cost consumers and the health care system in general.[9] And insurers continue to focus on their profits, even as Americans continue to struggle to get the care they need. For example, the Centers for Medicare and Medicaid Services (CMS) had to recently step in to stop insurers from denying claims for COVID-19 testing, as well as to increase compliance with COVID-19 relief legislation that required that plans cover such tests without cost sharing.[10]

Employer-Sponsored Insurance Failed at the Worst Possible Time

Another absurdity of our system, where more than half of all Americans depend on insurance provided through their job, was also laid bare by COVID-19 pandemic. Americans are always at risk of losing coverage through job loss, especially during an economic downturn and catastrophically so during a downturn caused by a global pandemic. Around 22 million Americans lost their job due to COVID-19, meaning millions also lost their insurance during a global pandemic.[11] While Congress recently passed legislation that would help address the huge loss of health insurance coverage, the scope of the reforms are limited and so Americans will continue to struggle without a comprehensive solution like Medicare for All.

Compounding the overall uninsured and underinsured rates is that many industries deemed to be essential have among the highest uninsured rates for their employees. A recent Public Citizen analysis found high rates of uninsured workers across several industries deemed essential.[12] Prior to the pandemic, more than half of all agricultural workers were uninsured, while around one in four workers across construction, home care, and restaurant workers lacked insurance. [Figure 1]

Image
Figure 1 – Uninsured Rate by Employment Category for Frontline Industries

Figure note: Data are based on a number of academic and governmental sources.[13]

Even before COVID-19, paying for health insurance coverage for their workforces was a huge burden for employers, hurting their competitiveness. If an employer does not provide insurance to its employees, it may struggle to attract and retain top-level talent. And if an employer does choose to provide health insurance, the rising annual costs may mean fewer wage increases, less generous plans, cuts to other benefits or perhaps even challenges to their ability to stay in business.

Small businesses – which have been hit the hardest under COVID-19 – were already facing the biggest challenges providing health insurance. Because of their size and the lack of economies of scale, small businesses often struggle to afford insurance for their employees. They face a significant disadvantage when negotiating with insurers and end up paying higher prices than larger companies. Employers with fewer than 10 employees face premiums nearly 20% higher, for the same benefits, than those paid by large businesses, and employers with 10 to 25 employees can expect to pay around 10% more.[14]

Under Medicare for All, everyone would have consistent coverage regardless of their employment status or employer. And because Americans would have their choice of providers, instead of facing the narrow networks their employers choose for them, they would face fewer challenges getting care, especially during a pandemic where some hospitals and providers are overwhelmed by demand.[15]

Hospitals Focused on Profit and Revenue Were Unable to Respond To COVID-19 While Safety Net Hospitals Faced Closure

Our current system creates incentives for hospitals to maximize profit and revenue, for example, by building expensive new hospital wings or buying unneeded equipment and then pressuring providers to refer patients for care to utilize those expensive investments, instead of furnishing the most sensible and necessary care. This has led to some particularly pernicious practices, including hospitals finding that debt collection can be more profitable than providing care and that hospitals can forgo charging a patient’s insurer and instead target patients’ accident settlements to increase hospital revenue, leading to patients facing huge bills and being hounded by debt collectors if they fail to pay them.[16] For example, the New York Times reported that a single hospital system in New York sued more than 2,500 patients even during the COVID-19 pandemic, a time when many families found their budgets stretched to the breaking point.[17] At the same time, hospitals continue to fight against any accountability as they game the system through charging exorbitant prices while slowing down any efforts at transparency regarding the prices they charge for care.[18]

Even before the pandemic, private equity companies were already consolidating hospital systems (many of which were then moving profitable specialties to other facilities) and contracting with certain provider types and taking them all out of insurance networks to allow charging exorbitant prices directly to patients through surprise bills.[19] This focus on profit and revenue meant that many hospitals were already in a precarious financial position – especially hospitals in rural and urban areas where it can be less profitable to provide care – and hospital closures left many communities with limited access to care even prior to the pandemic.[20]

In addition, many hospitals use just-in-time supply chains that can be brittle, especially during a surge in demand resulting from a pandemic, which led to shortages of key medicines, materials, and personal protective equipment (PPE).[21] These shortages place providers at risk, leading to reports of hospitals hoarding PPE and accusations that hospitals muzzled providers who spoke out about unsafe conditions due to a lack of access to PPE.[22]

Medicare for All would use comprehensive budgets negotiated between the government and health care institutions (such as hospitals and nursing homes) rather than the current approach of institutions making investments based on increasing profits or revenue. Known as global budgets, this approach would allow better control of overall spending while ensuring everyone can access needed services. These global budgets would allow hospitals on which communities depend to stay open by ensuring consistent funding year to year as well as providing emergency funding to be able to better respond to pandemics or natural disasters.

Nursing Homes Were Overwhelmed and Understaffed With Deadly Consequences for Patients

Historical under funding of long-term care – the majority of long-term care are funded by Medicaid at minimal rates – left many nursing homes unprepared for a pandemic and already struggling to contain infectious diseases.[23] And with seniors at among the highest risk for COVID-19 complications and deaths, it is no wonder that COVID-19 tore through nursing homes and other institutional settings. As the U.S. continues to lack a comprehensive and coherent approach to guaranteeing access to needed long-term services and supports, as described below, it falls to family members, state programs, and, overwhelmingly, Medicaid to bear the burden of funding long-term care, something it was never intended to do when it was passed.

The current system pushes people into nursing homes instead of home and community-based services (HCBS), despite such services being less expensive and often more desirable to patients than nursing home care. Such settings can be crowded and more likely to lead to the spread of infectious disease.[24] This is because state Medicaid programs are required to cover nursing home care, while HCBS is optional for states to provide. As such, the availability of home and community-based services varies widely by state. Several states have expanded access to home and community-based services coverage through requesting waivers of certain federal Medicaid requirements.[25]

Further, because many of the workers are paid poorly, they may work at multiple facilities or also contract with a home health agency. The intimate nature of this life-sustaining work limits the ability for social distancing, placing both workers and their patients at risk. In addition, the bias in funding toward institutional long-term care may have contributed to the spread of COVID-19 because seniors were often unable to social distance in nursing homes or other similar settings. Even before the COVID-19 crisis, the focus on profits in nursing homes was leading to increased deaths, according to a recent study that found that private-equity owned nursing homes had higher mortality rates than others.[26]

Around 70% of people over 65 will require at least some long-term care in their lifetimes.[27] Given our changing demographics—by 2030 all baby boomers will be 65 or older and by 2035 Americans age 65 and older will outnumber the number of children under 18 for the first time in U.S. history—we must ensure that we are providing access to needed long-term care in the most humane and efficient way possible, with the potential to also help limit the spread of future pandemics.[28] By including comprehensive long-term care coverage without cost-sharing and focusing on home and community based care, Medicare for All would meet both of these goals and begin the crucial transition from the institutional bias of our current long-term care system to a system that serves patients in the setting and community of their choice.

Underfunded Public Health System Struggled to Meet Demand for Testing, Contact Tracing, and Medical Supplies

Even though the U.S. spends far more than any comparably wealthy country on health care, public health spending, including prevention, preparedness, and adequate PPE and others supplies, has declined in recent decades.[29] At the same time as corporations funnel health spending into more profitable areas, as highlighted in the above sections, a smaller and smaller proportion of health spending has gone to public health.[30] As a result, many states’ public health infrastructure has struggled to meet the needs of the communities they serve on any given day, whether that be to address chronic health diseases blooming from early childhood or to provide affordable and appropriate care to its low-income population. These failures became particularly acute during the COVID-19 crisis and meant that the U.S. failed to even be able to keep up with other comparably wealthy countries when it came to things like testing and contact tracing.[31]

COVID-19 has been the largest public health emergency this country has faced in a century. However, our public health system has historically shown its importance through helping address emergencies, including the September 11th terrorist attacks, outbreaks of other contagious diseases, and extreme flu seasons. Yet the system continues to lack the resources required in times of need. Despite being a pillar of federal preparedness planning, funding for public health has fluctuated in recent years in response to congressional and presidential priorities as well as public health emergencies. [Figure 2]

Image
Figure 2 – Funding for Various Public Health Programs, 2000-2019

In analyzing two decades of Department of Health and Human Services (HHS) funding, Public Citizen found that the public health infrastructure lacks a strong foundation as funds are unstable and have fluctuated over time, with cuts taking place under both recent Democratic and Republican administrations.[32] For example, the Affordable Care Act (ACA) initially created the Prevention and Public Health Fund (PPHF) in 2010, and included a promise to dedicate $15 billion to improve the public health system.[33] However, two years later, former President Barack Obama cut $6.25 billion from the PPHF to pay for other policies followed by additional cuts. However, in response to the 2015 Zika outbreak, former President Obama pushed Congress to pass some additional public health funding.[34]

The funding increase tied to fighting Zika was consistent with the responses to other recent health care crises. Since 2000, national emergencies correlated with a dramatic infusion of money into the public health infrastructure. The Sept. 11, 2001, and anthrax terror attacks caused a spike in funding which was followed by another steep increase in response to the 2003 SARS outbreak. Similarly, the devastation from Hurricane Katrina sharply increased funding from 2005 to 2007 which then dramatically declined until it was raised in response to the 2009 H1N1 virus, but then was subsequently cut the following year. And, as discussed earlier, the implementation of the ACA caused huge spikes in funding for its first year, which then decreased until the 2015 global Zika scare.

While funding for public health continues to rise and fall, public health emergencies continue to get more expensive. Last year was the tenth consecutive year America endured eight or more disastrous events in a year that had damages exceeding $1 billion dollars. In 2020 alone, the nation experienced the beginning of COVID-19, hurricanes, storms, floods, fires, extreme temperatures, widespread outbreaks of Hepatitis A, thousands of opioid overdose deaths, spikes in lung diseases associated with vaping and mass casualty shootings.[35]

At the state level, public health infrastructure is largely funded by the federal government in the form of contracts and grants as well as by state allocations or designated taxes. However, during an economic downturn it can be difficult for states to rapidly approve additional funds, as they are generally unable to take on debt. Even with infusions of cash from the federal government in response to specific crises, local officials can struggle to cover all state and municipal costs. As a result, one study found that between 2010 and 2019 only 6 states experienced an increase in the number of public health staff, while many states remained stagnant and others experienced as much as a 30% drop in total staff.[36]

The significant shortfall in public health spending in recent decades is a contributing factor to the challenges we are experiencing with the current COVID-19 emergency, including an overstretched health care workforce, a lack of proper protective equipment, and failures by the Trump Administration and several states, all contributing to unnecessary suffering and death.[37]

The variance in public health expenditures per capita is drastically different across states, limiting communities’ access to health care services and producing serious health disparities throughout the nation. For example, in 2020 Mississippi and Pennsylvania spent $60 and $61 per person, respectively on non-hospital health care, Hawaii and Massachusetts spent $205 and $144, respectively.[38] Further, the majority of each states’ increase in spending has failed to keep up with the rate of health care inflation, meaning states are expected to address increasingly expensive emergencies without adequate resources.

In addition, the fragmented nature of the U.S. health care system makes it harder for any one agency or group to track how rapidly diseases, including the coronavirus, spread. Countries that had more unified systems were better able to roll out testing, track the spread of the disease via a central information hub, and intervene appropriately. The U.S., on the other hand, had to negotiate with numerous private insurers, issue regulations or orders for multiple public insurance programs, and figure out how handle testing and treatment for the uninsured. Other countries also did not need to rely on private companies voluntarily reducing their profit margins to provide affordable care in a time of crisis.[39]

By rolling out tests more quickly and ramping up to address the COVID-19 crisis without requiring coordination of as many stakeholders, countries like Taiwan and New Zealand were able to react quickly and begin testing widely.[40] In addition, many wealthy countries with universal health care systems were simply better prepared than the U.S. to treat patients with serious COVID-19 symptoms. For example, while the average Organization for Economic Co-operation and Development (OECD) country has 5.4 hospital beds per 1,000 people, the U.S. only has around half of that capacity at 2.8 beds per 1,000 people.[41] By comparison, some countries, such as Japan and Germany, have much higher capacity, with 13.1 and 8.1 per 1,000, respectively. The lack of adequate resources led to heartbreaking situations where doctors and nurses in the U.S. had to choose who would receive treatment and who would be left to die.[42]

Under Medicare for All, public health spending and preparedness would be fully funded, meaning a healthier population, which would help keep health care costs lower over time, and adequate resources to respond to crises, which would ensure we never again experience the chaotic and inept response that we saw in reaction to COVID-19. And because the government would be better able to track diseases, through consistent reporting requirements, and roll out testing or treatments through centralized purchasing and distribution, the country’s health care system would be nimbler and more coherent.

Finally, Medicare for All would be better able to disburse funds in emergency situations and to purchase necessary supplies, such as PPE or testing materials, and machinery, such as ventilators or respirators, during a crisis and get them where they need to go in a timely manner. Unlike our current health care system, Medicare for All would include specific funding for dealing with pandemics or other health emergencies that could be distributed quickly without requiring additional legislation. The United States must never again be left unprepared for mass health crises like COVID-19.

Existing Disparities Increased Deaths in Many Communities

After explaining how the health care system puts profit over patients and leads to underfunding of public health, it is no wonder that the U.S. entered into the COVID-19 pandemic with some of the starkest health disparities of any comparably wealthy country.[43] Even before the pandemic, Americans faced the highest rates of unmet need of any comparably wealthy country. In 2019, a third of Americans reported that they or a family member had avoided going to the doctor when sick or injured during the previous year due to cost.[44]

Our broken health care system, insufficient environmental protections and widening income and wealthy inequality, among other factors, COVID-19 further exacerbated those already poor health outcomes. Among the most concerning statistics, given the potential for COVID-19 to strike patients with respiratory illness particularly hard, the U.S. has much higher rates of asthma hospitalizations – nearly 90 hospitalizations per 100,000 people. This is double the average of comparable countries, around 42 hospitalizations per 100,000.[45] Further, Americans already are significantly more likely to die of chronic respiratory disease, cardiovascular disease, diabetes or cancer than people in comparably wealthy countries with universal health care systems.[46] Of the 246 million individuals in the country that are over the age of 18, 41.4 million of them are at high risk for a more serious illness if they contract COVID-19 due to an underlying medical condition.[47]

As COVID-19 spread around the nation, the CDC highlighted two communities that were most at risk for significant illness or death, those 65 and older and those with serious chronic diseases.[48] The chronic conditions that are of highest risk are asthma and lung disease, heart disease, unmanaged diabetes, severe obesity, and a weakened immune system due to HIV or cancer. While the nation suffers from high rates of each of these conditions, there is a growing health gap across race and ethnicity. For example, Hispanic and non-Hispanic Black adults had a 47% and 46.8%, respectively, higher prevalence of obesity than non-Hispanic White adults[49]. If looking at rates of diabetes, African Americans have a 77% higher chance of being diagnosed than whites, while Hispanics have a 66% higher chance.[50]

Further, racial and ethnic disparities resulting from institutional racism, including historical underfunding of care for communities of color, ongoing wealth and income gaps, and suppression of voting and political power to address these inequalities, have led to higher rates of morbidity and mortality for Black and Brown Americans. In addition, historical forces that led to disproportionate representation in lower-waged, frontline jobs and increased the risk of overcrowding in workplaces and homes in many parts of the country meant more people of color in these communities had a higher likelihood of contracting the coronavirus.[51]

People of color make up the majority of essential workers, especially in the food industry and agriculture where they represent more than 50% and 75% of the industries, respectively.[52] Essential positions require employees to come to work every day, increasing an individual’s risk to be exposed the COVID-19. Many essential workers had to fend for themselves in finding personal protective equipment, had little or no sick leave, and many were reluctant to get tested or report symptoms or a positive COVID-19 test for fear of losing their job.[53]

Further, the lack of coverage and basic worker protections for millions of nonimmigrant guestworkers and undocumented workers before and during the COVID-19 pandemic has meant that workers least able to protect themselves are, unsurprisingly, among the most likely to have contracted the coronavirus. Limited coverage options for guestworkers and the undocumented meant particular risk for certain communities and many essential industries that are dependent on employing non-citizens. And with the refusal of the Occupational Safety and Health Administration (OSHA) to deliver more than a slap on the wrist to corporations, even for violations that led to the death of workers, it is no wonder so many communities experienced outbreaks with slaughterhouses, agricultural facilities, or factory settings as their epicenter.[54]

While Medicare for All wouldn’t instantly undo damage done by centuries of institutional racism and decades of for-profit health care, it could begin the process of addressing substantial racial and ethnic disparities. It would mean the end of private insurance exacerbating these disparities, both on the economic side and especially for health outcomes. Importantly, Medicare for All could affirmatively remediate substantial problems – not just by ensuring care for all, but providing a positive counterbalance to the negative health impacts of institutional racism and growing inequality. And through funding Medicare for All through progressive taxes, including a wealth tax, Medicare for All could also serve to help begin the process of narrowing economic inequality.

Conclusion

Under Medicare for All, our health care system would focus on health and wellbeing instead of generating profit and revenue for wealthy insurers. Hospitals, including many rural hospitals, currently at risk of closure would have the funds they need to serve their communities. Patients could get the long-term care they need in the setting of their choice. The U.S. would finally be able to ensure sufficient funding for public health, including future pandemics. And the nation could finally begin addressing massive health disparities in a comprehensive way.

As the pandemic has shown, everyone depends on the health care system throughout their lives. Whether we face a public health emergency like a global pandemic or simply need to meet routine medical needs, Medicare for All would ensure necessary treatments are available to everyone regardless of their ability to pay.

There would be no out-of-pocket costs or sudden loss of coverage, for example, due to unemployment, to get in the way of Americans receiving the care they need. Small businesses would not be further stressed by providing health care for their employees. In addition, under Medicare for All, Americans would have the freedom to choose a doctor or hospital to receive care wherever is most convenient during a crisis, instead of facing the additional burden of finding providers within narrow private insurance networks which may get overwhelmed during a pandemic.

Footnotes

[1]As of March 11, 2021, the global number of cases was 118,328,593 and the number of U.S. cases was 29,191,168 (24.7%). The total number of deaths was 2,624,833 and the total number of U.S. deaths was 530,013 (20.2%).

Center for Systems Science and Engineering at Johns Hopkins University, COVID-19 Dashboard (2021), https://bit.ly/3euGjhz

[2]Judith Rodin and David de Ferranti, Universal Health Coverage: The Third Global Health Transition?, 380 The Lancet 861-862, 861 (2012).

[3]Steffie Woolhandler, David U. Himmelstein, Sameer Ahmed, et al., 397 Public Policy and Health in the Trump Era, 705, 708-714 (2021).

[4]Medicare for All would improve traditional Medicare and expand it to everyone in the U.S. with no out-of-pocket costs or premiums. Care would be provided in the setting and by the provider of each person’s choice as there would no longer be narrow insurer networks to deal with. It would also mean that everyone would have coverage throughout their lifetime, regardless of their employment status.

[5]The Commonwealth Fund, Health Insurance Coverage Eight Years After the ACA, 5 (2019), https://bit.ly/3rFsrVJ.

[6]Stan Dorn and Rebecca Gordon, Families USA, The Catastrophic Cost of Uninsurance: COVID-19 Cases and Deaths Closely Tied to America’s Health Coverage Gaps, 1, (2021), https://bit.ly/38vUKOQ.

[7]M. McLaughlin, F. Khan, and S. Pugh, et al., County-Level Predictors of COVID-19 Cases and Deaths in the United States: What Happened, and Where Do We Go from Here? Clinical Infectious Diseases 1729, 1736 (2020).

[8]Reed Abelson, Major U.S. Health Insurers Report Big Profits, Benefiting From the Pandemic, The New York Times (August 5, 2020), https://nyti.ms/3bC26C5.

[9]Steffie Woolhandler and David U. Himmelstein, Single-Payer Reform: The Only Way to Fulfill the President’s Pledge of More Coverage, Better Benefits, and Lower Costs, 166 Annals of Internal Medicine 587-588, 588 (2017).

[10]Nick Paul Taylor, CMS Moves to Stop COVID-19 Testing Denials, Cost Sharing in Private Plans, MedTech Dive (March 1, 2021), https://bit.ly/3t352Oe.

[11]Jonathan Ponciano, It Could Take 4 Years to Recover The 22 Million Jobs Lost During Covid-19 Pandemic, Moody’s Warns, Forbes (November 30, 2020), https://bit.ly/3rGvY5U.

[12]Public Citizen, Holes in the Safety Net, 1 (October 2020), https://bit.ly/3rF6s16.

[13]Id.

[14]Claire Martin, In the Health Law, an Open Door for Entrepreneurs, The New York Times (November 23, 2013), https://nyti.ms/2O463R5.

[15]Many hospitals were overwhelmed by surges in COVID-19, creating challenges for patients who needed care from seeking care at their normal facility. This meant facing out-of-network charges and even surprise bills when pursuing care.

Mike Baker and Sheri Fink, At the Top of the Covid-19 Curve, How Do Hospitals Decide Who Gets Treatment?, The New York Times (March 31, 2020), https://nyti.ms/3bGx4ZZ.

[16]John Tozzi, A Hospital Giant Discovers That Collecting Debt Pays Better Than Curing Ills, Bloomberg (December 18, 2017), https://bloom.bg/30Bj0uA.

Sarah Kliff and Jessica Silver-Greenberg, How Rich Hospitals Profit From Patients in Car Crashes, The New York Times (February 1, 2021), https://nyti.ms/3rJuLLi.

[17]Brian M. Rosenthal, One Hospital System Sued 2,500 Patients After Pandemic Hit, The New York Times (January 5, 2021), https://nyti.ms/3l8Dcx5.

[18]David Lazarus, Medicare Says a Procedure is Worth $5,869. This Hospital Imposed a 1,200% Markup, Los Angeles Times (January 26, 2021), https://lat.ms/3tgatcN.

Alexandra Ellerbeck, Hospitals Drag Feet on New Regulations to Disclose Costs of Medicare Services, The Washington Post (January 25, 2021), https://wapo.st/3t9R1hJ.

[19]Joseph D. Bruchs, Suhas Gondi, and Zirui Song, Changes in Hospital Income, Use, and Quality Associated with Private Equity Acquisition, 180 JAMA Internal Medicine 1428, 1429-1432 (2020).

[20]U.S. Government Accountability Office, Rural Hospital Closures: Affected Residents Had Reduced Access to Health Care Services (2021), https://bit.ly/30C8iUp.

[21]Lizzie O’Leary, The Modern Supply Chain is Snapping, The Atlantic (March 19, 2020) https://bit.ly/2OfReBn.

[22]Alicia Gallegos, Hospitals Muzzle Doctors and Nurses on PPE, COVID-19 Cases, Medscape (March 25, 2020) https://wb.md/3tc1TeZ.

[23]U.S. Government Accountability Office, Infection Control Deficiencies Were Widespread and Persistent in Nursing Homes Prior to COVID-19 Pandemic (May 2020), https://bit.ly/3eEPRqF.

[24]Id.

[25]Erica L. Reaves and Marybeth Musumeci, Kaiser Family Foundation, Medicaid and Long-Term Services and Supports: A Primer (December 2015), https://bit.ly/2CAzEPY.

[26]Atul Gupta, Sabrina T. Howell, Constantine Yannelis, and Abhinav Gupta, National Bureau of Economic Research, Does Private Equity Investment in Healthcare Benefit Patients? Evidence From Nursing Homes (February 2021), https://bit.ly/30O1h2U.

[27]Emily Gurnon, The Staggering Prices of Long-Term Care 2017, Forbes (September 26, 2017), https://bit.ly/2W5hFZp.

[28]Press Release, U.S. Census Bureau, Older People Projected to Outnumber Children for First Time in U.S. History (Sep. 6, 2018), https://bit.ly/2p8zoQY.

[29]David U. Himmelstein and Steffie Woolhandler, Public Health’s Falling Share of US Health Spending, 106 American Journal of Public Health 56, 56-57 (2016).

[30]Rabah Kamal and Julie Hudman, Peterson-KFF Health System Tracker, What Do We Know About Spending Related to Public Health in the U.S. and Comparable Countries?, at 2 (September 2020), https://bit.ly/3lg1IN6.

[31]Eric C. Schneider, Failing the Test — The Tragic Data Gap Undermining the U.S. Pandemic Response, 383 The New England Journal of Medicine 299, 299-231 (2020).

[32]We analyzed two decades of funding the Department of Health and Human Services (HHS) to identify spending levels across the Health Resources and Services Administration (HRSA), the Centers for Disease Control and Prevention (CDC), and General Department Management. These entities can be further broken down by the programs that directly impact public health. Our analysis grouped programs into the following categories; infectious disease, the Public Health Preparedness and Response Fund, hospital preparedness and the Public Health Social Services Emergency Fund, rural health, healthcare workforce, and health centers. One limitation of the data for tracking the rate of for each of these programs from 2000 to 2019 was that programs’ names or the structure of the programs were altered in some years, requiring us to classify them manually.

[33]Funding: PPHF, Centers for Disease Control and Prevention (viewed on March 11, 2021), https://bit.ly/3qBuzMJ.

[34]James W. Begun, and Jan K. Malcolm. Leading Public Health: A Competency Framework. (Springer Publishing Company, 2014).

[35]Colorado School of Public Health, The National Health Security Preparedness Index: 2020 Release 2 (2020), https://bit.ly/2Q0XBJ9.

[36]Lauren Weber, Laura Ungar, Michelle R. Smith, et al., Hollowed-Out Public Health System Faces More Cuts Amid Virus, Kaiser Health News (July 1, 2020), https://bit.ly/3lkcj9J.

[37]Amanda Holpuch, US could have averted 40% of Covid deaths, says panel examining Trump’s policies, The Guardian (February 11, 2021) https://bit.ly/38GLMOB.

[38]Public Health Impact: Public Health Funding, America’s Health Ranking (viewed on March 15, 2021), https://bit.ly/3qOxH8b.

[39]Public Citizen, Health Insurers’ Offers of Free COVID-19 Care Are Less Generous Than They Appear (May 2020), https://bit.ly/3cu24vs.

[40]Jennifer Summers, Hao-Yuan Cheng, and Hsien-Ho Lin, et al., Potential Lessons From the Taiwan and New Zealand Health Responses to the COVID-19 Pandemic, 4 The Lancet Regional Health Western Pacific 1, 1-3 (2020)

[41]Dylan Scott, Coronavirus is Exposing All of the Weaknesses in the US Health System, Vox (March 16, 2020), https://bit.ly/3eICcyO.

[42]Mike Baker and Sheri Fink, At the Top of the Covid-19 Curve, How Do Hospitals Decide Who Gets Treatment?, The New York Times (March 31, 2020), https://nyti.ms/2OzCWeP.

[43]Ezekiel J. Emanuel, Emily Gudbranson, and Jessica Van Parys, et al., Comparing Health Outcomes of Privileged US Citizens With Those of Average Residents of Other Developed Countries, 181 JAMA Internal Medicine 339, 339-342 (202).

[44]Lydia Saad, More Americans Delaying Medical Treatment Due to Cost, Gallup (December 9, 2019), https://bit.ly/3tnOvVm.

[45]Irene Papanicolas, Liana R. Woskie, and Ashish K. Hja, Health Care Spending in the United States and Other High-Income Countries, 319 JAMA 1024, 1032 (2018).

[46]World Health Organization, World Health Statistics 2018: Monitoring Health for the SDGs, Sustainable Development Goals 31 (2018), https://bit.ly/3rP0smo.

[47]Wyatt Koma, Tricia Neuman and Gary Claxton, et al., Kaiser Family Foundation, How Many Adults Are at Risk of Serious Illness If Infected with Coronavirus? Updated Data 1 (April 2020), https://bit.ly/30MwqUA.

[48]National Association of Chronic Disease Directors, Chronic Disease and COVID-19: What You Need to Know 1 (2020), https://bit.ly/2Q6riZo.

[49]Racial and Ethnic Approaches to Community Health (REACH), Centers for Disease Control and Prevention (viewed on March 15, 2021), https://bit.ly/38ZNRpl.

[50]Kenneth E. Thorpe, Kathy Ko Chin, and Yanira Cruz, et al., The United States Can Reduce Socioeconomic Disparities By Focusing On Chronic Diseases, Health Affairs Blog (August 17, 2017), https://bit.ly/3tmV0HL.

[51]Hye Jin Rho, Hayley Brown and Shawn Fremstad, Center for Economic And Policy Research, A Basic Demographic Profile of Workers in Frontline Industries 3 (April 2020), https://bit.ly/3cDdltg.

Labor Force Statistics from the Current Population Survey, U.S. Bureau of Labor Statistics (viewed on March 15, 2021), https://bit.ly/2OrJg8l.

[52]Celine McNicholas and Margaret Poydock, Who are Essential Workers? A Comprehensive Look at Their Wages, Demographics, and Unionization Rates, EPI Working Economics Blog (May 19, 2020), https://bit.ly/3cBHfya.

Trish Hernandez and Susan Gabbard, U.S. Department of Labor, Findings from the National Agricultural Workers Survey (NAWS) 2015-2016: A Demographic and Employment Profile of United States Farmworkers (January 2018), https://bit.ly/3cwoSLe.

[53]Daniel Schneider and Kristen Harknett, The Shift Project, Essential and Vulnerable: Service-Sector Workers and Paid Sick Leave https://bit.ly/2Npbwb4.

[54]Irina Ivanova, U.S. Workplace Safety Enforcer Failed During COVID-19, Watchdog Says, CBS News (March 2, 2021), https://cbsn.ws/3qQULmy.

Kimberly Kindy, More than 200 Meat Plant Workers in the U.S. Have Died of Covid-19. Federal Regulators Just Issued Two Modest fines., The Washington Post (September 13, 2020), https://wapo.st/3vuU2uQ.
admin
Site Admin
 
Posts: 36180
Joined: Thu Aug 01, 2013 5:21 am

Re: U.S. government gave $3.7 million grant to Wuhan lab at

Postby admin » Sun Mar 28, 2021 3:28 am

Trump brags to Fox host Laura Ingraham that he did opposite of what top expert advised amid pandemic: "I didn't really listen to [Dr. Anthony Fauci] too much, because I was doing the opposite of what he was saying"
by Bob Brigham
March 26, 2021 8:30AM (UTC)

NOTICE: THIS WORK MAY BE PROTECTED BY COPYRIGHT

YOU ARE REQUIRED TO READ THE COPYRIGHT NOTICE AT THIS LINK BEFORE YOU READ THE FOLLOWING WORK, THAT IS AVAILABLE SOLELY FOR PRIVATE STUDY, SCHOLARSHIP OR RESEARCH PURSUANT TO 17 U.S.C. SECTION 107 AND 108. IN THE EVENT THAT THE LIBRARY DETERMINES THAT UNLAWFUL COPYING OF THIS WORK HAS OCCURRED, THE LIBRARY HAS THE RIGHT TO BLOCK THE I.P. ADDRESS AT WHICH THE UNLAWFUL COPYING APPEARED TO HAVE OCCURRED. THANK YOU FOR RESPECTING THE RIGHTS OF COPYRIGHT OWNERS.


Over 30 million Americans have contracted coronavirus, with over 546,000 fatalities, but former President Donald Trump took to Fox News on Thursday to brag about refusing to follow the medical advice of Dr. Anthony, Fauci, the country's top infectious disease expert.

Trump made his comments during a telephone interview with Fox News personality Laura Ingraham.

"If you saw him throw out the first pitch in Washington, right? He is a better pitcher than he is as what he does," Trump taunted.

"But if you really look, I didn't really listen to him too much, because I was doing the opposite of what he was saying," Trump admitted.
admin
Site Admin
 
Posts: 36180
Joined: Thu Aug 01, 2013 5:21 am

Re: U.S. government gave $3.7 million grant to Wuhan lab at

Postby admin » Sun Mar 28, 2021 3:49 am

Lancet Study Finds 40 Percent of U.S. COVID-19 Deaths Could Have Been Avoided
by Elliot Hannon
slate.com
Feb. 11, 20218:23 AM

NOTICE: THIS WORK MAY BE PROTECTED BY COPYRIGHT

YOU ARE REQUIRED TO READ THE COPYRIGHT NOTICE AT THIS LINK BEFORE YOU READ THE FOLLOWING WORK, THAT IS AVAILABLE SOLELY FOR PRIVATE STUDY, SCHOLARSHIP OR RESEARCH PURSUANT TO 17 U.S.C. SECTION 107 AND 108. IN THE EVENT THAT THE LIBRARY DETERMINES THAT UNLAWFUL COPYING OF THIS WORK HAS OCCURRED, THE LIBRARY HAS THE RIGHT TO BLOCK THE I.P. ADDRESS AT WHICH THE UNLAWFUL COPYING APPEARED TO HAVE OCCURRED. THANK YOU FOR RESPECTING THE RIGHTS OF COPYRIGHT OWNERS.


The British medical journal the Lancet, on Wednesday, published a damning assessment of Donald Trump’s presidency and its impact on Americans’ health, concluding that 40 percent of the nearly 500,000 COVID-19 deaths in the U.S. over the past year were avoidable. The journal came to the conclusion by comparing the U.S. health outcomes on the coronavirus—the country leads the world in COVID deaths and confirmed cases with more than 27 million—with the weighted average of other G-7 nations. So it’s not a wildly abstract conclusion to draw: the U.S. could have saved hundreds of thousands of lives if it had just performed similarly to its economic peers.

The report assailed Trump for his response to the pandemic, but emphasized that the disastrous response to the virus’s spread was the result of years of destructive public policy decisions on health that extended well beyond the Trump years. From the Lancet:

Many of the cases and deaths were avoidable. Instead of galvanizing the U.S. populace to fight the pandemic, President Trump publicly dismissed its threat (despite privately acknowledging it), discouraged action as infection spread, and eschewed international cooperation. His refusal to develop a national strategy worsened shortages of personal protective equipment and diagnostic tests. President Trump politicized mask-wearing and school reopenings and convened indoor events attended by thousands, where masks were discouraged and physical distancing was impossible.


The result, the Lancet notes, is more than 450,000 deaths where “about 40 percent of which could have been averted had the U.S. death rate mirrored the weighted average of the other G7 nations.” But the trajectory of the U.S. falling behind G-7 nations in life expectancy is nothing new, and the gap has grown over the past decade even before the coronavirus exacerbated existing deficiencies in the U.S. health system. The number of excess deaths in the U.S. when compared to similar countries in the G-7 already stood at more than 450,000 in 2018 alone—a number that has been climbing for decades. Most of those unnecessary deaths in the U.S. are in people under the age 65, such that, “if U.S. death rates were equivalent to those of other G7 nations, two of five deaths before age 65 years would have been averted,” the Lancet notes. “To put this number in context, the number of missing Americans each year is more than the total number of COVID-19 deaths in the USA in all of 2020.”
admin
Site Admin
 
Posts: 36180
Joined: Thu Aug 01, 2013 5:21 am

Re: U.S. government gave $3.7 million grant to Wuhan lab at

Postby admin » Sun Mar 28, 2021 3:55 am

Autopsy of a pandemic: 6 doctors at the center of the US Covid-19 response
by CNN
Published March 26, 2021 7:54 am


Dr. Birx drops bombshell about US Covid-19 deaths
Mar 29, 2021
Dr. Deborah Birx, the coronavirus task force coordinator until former President Donald Trump, revealed in an interview with CNN's Dr. Sanjay Gupta that the number of coronavirus deaths could have been "decreased substantially" if cities and states across the country had aggressively applied the lessons of the first surge toward mitigation last spring, potentially preventing the surges that followed.
"I look at it this way. The first time we have an excuse," Birx said. "There were about a hundred thousand deaths that came from that original surge. All of the rest of them, in my mind, could have been mitigated or decreased substantially."


This past January, just a few days after the inauguration of President Joe Biden, six of the doctors responsible for the previous administration’s Covid-19 response agreed to sit down — in strict confidence — and talk with me about the events of the past year.

Over the period of a few weeks, in Houston, Washington, DC, and Baltimore, our team secured nondescript, large hotel ballrooms with plenty of space and ventilation to allow these extraordinary one-on-one conversations to take place with Dr. Deborah Birx, Dr. Anthony Fauci, Dr. Brett Giroir, Dr. Stephen Hahn, Dr. Robert Kadlec and Dr. Robert Redfield.

Given our shared medical backgrounds, I explained to each of the doctors that I was going to frame the discussions in a way that would be tough, but familiar: as an autopsy.

We were going to meticulously dissect and discuss how the United States became home to the worst Covid-19 outbreak on the planet.

There is no question an autopsy or post mortem is painful and gruesome to witness. And, it does nothing for the deceased patient on the table — in this case, the nearly 550,000 Americans who have died from Covid-19. And, yet we do it because there are often important lessons to learn; lessons that can still be applied during this ongoing pandemic and for future pandemics, which all of the doctors agree is inevitable. Autopsies are particularly important if the death was thought to have been preventable.

And here again, the doctors were in agreement — while Covid-19 is a serious disease, the vast majority of deaths in the United States could’ve been avoided.

Most of the doctors I interviewed are household names nowadays, but you have probably only previously heard them in soundbites or seen them briefly at the lectern in the White House briefing room. All but one of the doctors are private citizens now, unbridled and unrestrained by the watchful eyes of the White House, and they had a lot to say. Our cathartic and frank discussions lasted hours on end, covered a wide range of topics and were at times horrifying in what they revealed.

The first cut

When I met up with Dr. Robert Redfield on a snowy February day in Baltimore, his mood was both reflective and determined. A trained virologist, Redfield was tapped by President Donald Trump back in 2018 to lead the CDC after a long career in public health. Before the pandemic, the new director had been largely focused on two other epidemics: opioids and HIV/AIDS. Alongside his colleagues Fauci and Birx, Redfield has been best known for decades for his work as one of the world’s leading AIDS researchers.

As with his term as CDC director, Redfield’s earlier career had not been without controversy. In the ’80s and ’90s, as one of the Army’s top AIDS researchers, he was accused of overselling the effectiveness of a possible AIDS vaccine, though Redfield stood by his work. During the Covid-19 pandemic, critics argued Redfield failed to protect the credibility of the massive scientific agency he was tasked to lead and was outmaneuvered by an executive branch found to be meddling in science-based CDC guidance involving school closings and religious gatherings. Redfield dismissed those concerns, however. When I asked him if he felt prepared for the job, he told me, “I think I trained my whole life for this.”

When we sat down to talk, just days after his successor, Dr. Rochelle Walensky, had taken the helm at the CDC, Redfield wanted to start at the beginning: China.

While every doctor harbored deep suspicions about the information initially coming from China, Redfield was the most vocal about it. He believes the current pandemic began in Wuhan as a localized outbreak in September or October of 2019 — much earlier than the official timeline — and then spread to every province in China over the next couple of months. The United States wasn’t formally notified of the “mysterious cluster of pneumonia patients” until December 31, 2019. Those were critical weeks and months that countries around the world could’ve been preparing.

“So they had about a 30 day head start,” Kadlec affirmed days before I sat down with Redfield.

Kadlec was the HHS assistant secretary for preparedness and response, known as the ASPR. “They were already buying things on the market well in advance of what we were,” he told me. “Even things that were made here in the United States, we found that the domestic supplies were drying up because of foreign purchases.”

And while the rest of the world was told the only initial Covid-19 cases in China had originated from a wet market in Wuhan, Redfield is confident the evidence suggests that was simply not the case. According to Redfield, even his counterpart at the China CDC, Dr. George Gao, was initially left in the dark about the magnitude of the problem until early January. He described a private phone call he had with Gao in early January 2020, when Gao became distraught and started crying after finding “a lot of cases” among individuals who had not been to the wet market. Gao, Redfield says, “came to the conclusion that the cat was out of the bag.”

The initial mortality rates in China were somewhere between “5-10%,” Redfield told me. “I’d probably be cryin’ too,” he added.

One of the most significant things “that affected our success in this pandemic was not being allowed into China” earlier, he told me. Fauci echoed a similar sentiment when I asked him about it.

“I think it would have been a significant difference,” Fauci said. “I think if we had sent our people into Wuhan and been able to talk to the Chinese scientists in a conversation that might have lasted an hour, you could have gotten so much information right from the get go. They would have told us, don’t believe what you’re reading. This is spread asymptomatically. It spreads highly efficiently and it’s killing people.”

Neither President Trump’s calls to President Xi Jinping nor Secretary Alex Azar’s pleas to China’s minister of health could get them in, according to Redfield.

The question laid bare from our autopsy was, why?

The earliest symptoms

If US investigators had been allowed into China, there is something else they may have discovered: the origins of the virus. Where and how this outbreak began is not simply an exercise of curiosity, or an attempt to assign blame. It is a necessity for scientists and public health experts around the world to try and stop future pandemics.

So far, the official word has been that this pandemic started when the novel coronavirus was introduced through an intermediary species or jumped directly from a bat to a human, something that Redfield, the former head of the CDC, believes doesn’t make “biological sense.”

Reminding me that his career has been spent as a virologist, he told me “I do not believe this somehow came from a bat to a human. And at that moment in time, the virus came to the human, became one of the most infectious viruses that we know in humanity for human to human transmission … Normally, when a pathogen goes from a zoonot to human, it takes a while for it to figure out how to become more and more efficient.”

Without assigning intentionality, Redfield told me he believes the origin of the pandemic is a lab in China that was already studying the virus, exposing it to human cell cultures.

“Most of us in a lab, when trying to grow a virus, we try to help make it grow better, and better, and better, and better, and better, and better so we can do experiments and figure out about it. That’s the way I put it together.”

It is a controversial, politically charged theory — one the World Health Organization calls “extremely unlikely,” and there has been no clear evidence to support this “lab leak” theory.

Yet, more than a year after the outbreak, a team of WHO scientists inside Wuhan has still been unable to determine the definitive origin of the virus. At this point, it is not clear they ever will.

In response to the Biden administration’s call for more transparency from China about data from the earliest days of the outbreak, China released a statement out of its Washington embassy alleging that the United States is now “pointing fingers at other countries.” Meanwhile, Chinese officials and state media have been increasingly promoting an unsubstantiated, so-called “multiple-origin” theory, suggesting the pandemic may have started in various locations around the world, even a US military lab.

Final cause of death

Over nearly 20 hours of interviews, I asked each doctor the question that ends every autopsy. What do they believe was the final cause of death? What led to the preventable deaths of so many Americans?

From the role of leadership and the cost of unpreparedness to the obligations of citizens to care for one another, Redfield and the Covid doctors shared their painful lessons from the worst public health crisis of our lifetimes.

Their answers offer an illuminating and frightening glimpse into what exactly happened over the past year, and also a plan for how to handle the next one.

“As bad as this was,” Kadlec told me, “it could be worse. And there will be another pandemic, guaranteed.”
admin
Site Admin
 
Posts: 36180
Joined: Thu Aug 01, 2013 5:21 am

Re: U.S. government gave $3.7 million grant to Wuhan lab at

Postby admin » Fri Apr 02, 2021 9:23 pm

W.H.O. Inquiry on the Pandemic’s Origin: What We Know: Did Covid-19 come from animal markets? It’s unclear. Did it emerge from a lab? Also unclear. Here’s what a new W.H.O. report says — including questions that the agency’s own chief raised about the findings.
by Javier C. Hernández
New York Times
March 30, 2021

NOTICE: THIS WORK MAY BE PROTECTED BY COPYRIGHT

YOU ARE REQUIRED TO READ THE COPYRIGHT NOTICE AT THIS LINK BEFORE YOU READ THE FOLLOWING WORK, THAT IS AVAILABLE SOLELY FOR PRIVATE STUDY, SCHOLARSHIP OR RESEARCH PURSUANT TO 17 U.S.C. SECTION 107 AND 108. IN THE EVENT THAT THE LIBRARY DETERMINES THAT UNLAWFUL COPYING OF THIS WORK HAS OCCURRED, THE LIBRARY HAS THE RIGHT TO BLOCK THE I.P. ADDRESS AT WHICH THE UNLAWFUL COPYING APPEARED TO HAVE OCCURRED. THANK YOU FOR RESPECTING THE RIGHTS OF COPYRIGHT OWNERS.


Image
Members of the World Health Organization team that investigated the coronavirus’s origins gathered in Wuhan, China, last month. Credit...Aly Song/Reuters

More than a year after the coronavirus pandemic began, the World Health Organization released a report on Tuesday laying out theories on how the virus first spread to humans — but it is already raising more questions than answers, including from the health body’s own leader.

The report, drafted by a 34-member team of Chinese scientists and international experts who led a mission to Wuhan, China, examines a series of politically contentious questions, including whether the virus might have accidentally emerged from a Chinese laboratory.

Some members of the expert team have raised concerns about China’s refusal to share raw data about early Covid-19 cases. In an unusual move, Dr. Tedros Adhanom Ghebreyesus, the W.H.O.’s director-general, acknowledged those concerns while speaking about the report on Tuesday. He said he hoped future studies would include “more timely and comprehensive data sharing.”

Here’s what we know about the report.

The experts dismissed a lab leak theory.

For months, scientists, politicians and others outside China have promoted the theory that the virus might have emerged after a laboratory accident in China. While many experts doubt this theory, they have urged the W.H.O. team to rigorously investigate the possibility.

The report dismisses the lab leak theory outright, calling it “extremely unlikely.” The experts largely base their conclusion on conversations with scientists in Wuhan.

But Dr. Tedros, the W.H.O. chief, took the unexpected step of publicly raising doubts, saying that the theory required further investigation and that he was ready to deploy more experts to do so.

“I do not believe that this assessment was extensive enough,” he said on Tuesday at a briefing for member states on the report, according to prepared remarks released to the news media. “Further data and studies will be needed to reach more robust conclusions.”

The experts had said that officials at the Wuhan Institute of Virology, which houses a state-of-the-art laboratory known for its research on bat coronaviruses, assured them that they were not handling any viruses that appeared to be closely related to the coronavirus that caused the recent pandemic, according to meeting notes included in the report. They also said that staff members had been trained in security protocols.

The report noted that a separate laboratory run by the Wuhan Center for Disease Control and Prevention had moved in late 2019 to a new location near the Huanan Seafood Wholesale Market in Wuhan, where many early cases of Covid-19 emerged. The expert team said that there appeared to be no connection, writing that the lab had not reported any “disruptions or incidents caused by the move” and had not been doing research on coronaviruses.

Some critics have suggested that the team seemed to take the Chinese official position at face value and did not adequately investigate lab officials’ assertions.

Raina MacIntyre, who heads the biosecurity program at the Kirby Institute of the University of New South Wales in Sydney, Australia, said the report seemed to dismiss the idea of a lab leak “without strong evidence.”

“A lab accident is certainly a possibility,” she said.

The role of animal markets is still unclear.

The expert team concluded that the coronavirus probably emerged in bats before spreading to humans through an intermediate animal. But the team said there was not enough evidence to identify the species or to pinpoint where the spillover of the virus from animals first occurred.

Early in the pandemic, Chinese officials floated theories suggesting that the coronavirus outbreak might have started at the Huanan market. More than a year later, the role of animal markets in the story of the pandemic is still unclear, according to the report.

The expert team found that many early cases had no clear connection to Huanan market, which sold sika deer, badgers, bamboo rats, live crocodiles and other animals, according to vendor records cited in the report.

Among those initial confirmed cases, about 28 percent had links to the Huanan market and 23 percent were tied to other markets in Wuhan, while 45 percent had no history of market exposure, according to the report.

“No firm conclusion therefore about the role of the Huanan market in the origin of the outbreak, or how the infection was introduced into the market, can currently be drawn,” the report says.

It says that further studies of farms and wild animals in China are needed, and that more clues about the markets’ role may emerge.

The inquiry’s success will depend on China.

The expert team offers a long list of recommendations for additional research: more testing of wildlife and livestock in China and Southeast Asia, more studies on the earliest cases of Covid-19 and more tracing of pathways from farms to markets in Wuhan.

But it is unclear whether China, which has repeatedly hindered the W.H.O. inquiry, will cooperate. Chinese officials have sought to redirect attention elsewhere, suggesting that the virus could have emerged in the United States or other countries.

Experts say the delays in the inquiry have hurt the ability to prevent other pandemics.

“This delay has obviously compromised the ability of the investigation to reconstruct the origins of Covid-19 and identify ways of reducing the risk of such events happening again in the future,” said Michael Baker, a professor of public health at the University of Otago in New Zealand.

Javier C. Hernández is a China correspondent. He has covered the rise of the authoritarian state under Xi Jinping, the spread of social causes like the #MeToo movement and the plight of China’s most vulnerable citizens, including migrant workers and pollution victims. @HernandezJavier
admin
Site Admin
 
Posts: 36180
Joined: Thu Aug 01, 2013 5:21 am

Re: U.S. government gave $3.7 million grant to Wuhan lab at

Postby admin » Fri Apr 02, 2021 9:40 pm

Some Scientists Question W.H.O. Inquiry Into the Coronavirus Pandemic’s Origins: Those who still suspect the outbreak in China may have been caused by a lab leak or accident are pressing for an independent investigation.
by James Gorman
New York Times
March 4, 2021

NOTICE: THIS WORK MAY BE PROTECTED BY COPYRIGHT

YOU ARE REQUIRED TO READ THE COPYRIGHT NOTICE AT THIS LINK BEFORE YOU READ THE FOLLOWING WORK, THAT IS AVAILABLE SOLELY FOR PRIVATE STUDY, SCHOLARSHIP OR RESEARCH PURSUANT TO 17 U.S.C. SECTION 107 AND 108. IN THE EVENT THAT THE LIBRARY DETERMINES THAT UNLAWFUL COPYING OF THIS WORK HAS OCCURRED, THE LIBRARY HAS THE RIGHT TO BLOCK THE I.P. ADDRESS AT WHICH THE UNLAWFUL COPYING APPEARED TO HAVE OCCURRED. THANK YOU FOR RESPECTING THE RIGHTS OF COPYRIGHT OWNERS.


A small group of scientists and others who believe the novel coronavirus that spawned the pandemic could have originated from a lab leak or accident is calling for an inquiry independent of the World Health Organization’s team of independent experts sent to China last month.

While many scientists involved in researching the origins of the virus continue to assert that the SARS-CoV-2 pandemic almost certainly began in a leap from bats to an intermediate animal to humans, other theories persist and have gained new visibility with the W.H.O.-led team of experts’ visit to China. Officials with the W.H.O. have said in recent interviews that it was “extremely unlikely” but not impossible that the spread of the virus was linked to some lab accident.

The open letter, first reported in The Wall Street Journal and the French publication Le Monde, lists what the signers see as flaws in the joint W.H.O.-China inquiry, and state that it could not adequately address the possibility that the virus leaked from a lab. The letter further posits the type of investigation that would be adequate, including full access to records within China.

The W.H.O. mission, as with everything involving China and the coronavirus, has been political from the start as the international team’s members acknowledged.

Richard Ebright, a molecular biologist at Rutgers University and one of the scientists who signed the letter, said it grew out of a series of online discussions among scientists, policy experts and others who came to be known informally as the Paris group. Many of those who signed the letter were based in France and Dr. Ebright, who has been outspoken about the need to investigate a possible laboratory leak, said such discussion had been less vigorous in the United States.

He said that no one in the group thought that the virus had been intentionally created as a weapon, but they were all convinced that an origin in a lab through research or by accidental infection was as likely as a spillover occurring in nature from animals to humans.

Dr. Ebright said the letter was released because the Paris group expected to see an interim report from the W.H.O. on Thursday. The letter, he added, “was communicated to high levels of the W. H.O. on Tuesday.”

Asked to respond to the letter, Tarik Jasarevic, a spokesman for the W.H.O., replied in an email that the team of experts that had gone to China “is working on its full report as well as an accompanying summary report, which we understand will be issued simultaneously in a couple of weeks.”

The open letter noted that the W.H.O.’s study was a joint effort by a team of outside experts, selected by the global health organization, who worked along with Chinese scientists, and that the team’s report must be agreed on by all. The letter emphasized that the team was denied access to some records and did not investigate laboratories in China.

Findings by the team, the letter stated, “while potentially useful to a limited extent, represent neither the official position of the W.H.O. nor the result of an unrestricted, independent investigation.”

Without naming him, the letter criticized Peter Daszak, an expert in animal diseases and their connection to human health, who is the head of EcoHealth Alliance. The letter linked to articles about Dr. Daszak and said he had previously stated his conviction that a natural origin of the virus was most likely.

Dr. Daszak said the letter’s push to investigate a lab origin for the virus was a position “supported by political agendas.”

“I strongly urge the global community to wait for the publication of the report from the W. H.O. mission,” he added.

Filippa Lentzos, a senior lecturer in science and international security, at King’s College London, and one of the signers of the letter, said, “I think in order to get a credible investigation, it has to be more of a global effort in the sense that it should be taken to the U.N. General Assembly where all the nations of the world are represented and can vote on whether or not to give a mandate to the U.N. secretary general, to carry out this kind of investigation.”

Dr. David A. Relman, a professor of medicine and microbiology at Stanford University and a member of the intelligence community studies board at the National Academies of Science, Engineering and Medicine, an advisory body to the federal government, said he was “quite supportive” of the open letter.

“I completely agree, based on what we know so far, that the W.H.O. investigation appears to be biased, skewed, and insufficient,” he said in an email. “Most importantly, without full transparency and access to the primary data and records, we cannot understand the basis for any of the comments issued so far on behalf of the investigation or by W.H.O.”


At the same time, scientists working on coronaviruses continue to unearth and report evidence to support the natural evolution and spillover of the virus from animals.

Robert F. Garry, a virologist at Tulane University Medical Center, recently posted on the website Virological a report that is not yet peer-reviewed that described new evidence that aspects of the virus that seemed unusual at first had been found in new viruses in Japan, Thailand and Cambodia. He and his co-authors concluded, “These observations are consistent with the natural origin of SARS-CoV-2 and strongly inconsistent with a laboratory origin.”

He said that he was familiar with some of the views of the letter signers expressed in previous media appearances or on social media, involving speculation about ways the virus could have come from laboratory work, and that none of those views appeared in the letter.

Dr. Garry said the possible scenarios described in the letter were that “the Wuhan Institute of Biology either had SARS-CoV-2 or something very close to it before the outbreak. And for whatever reason, some grand conspiracy, they just didn’t want to tell anybody about it.”

He said he continued to believe that a lab origin was “next to impossible.” He said, “We need to look in animals.”

That seems to strike at the heart of the concerns of the Paris group, which is the nature of future research. Dr. Ebright said that everyone in the group was concerned about both wildlife surveillance and laboratory research into viruses as potentially increasing, not lessening the likelihood of future pandemics.

If either collecting samples in the wild or work with those samples in labs were implicated in the origin of the pandemic, he said, the need would be urgent “to assess whether benefits outweigh risks and if not to restrict those activities.”


James Gorman is a science writer at large and the host and writer of the video series “ScienceTake.” He joined The Times in 1993 and is the author of several books, including “How to Build a Dinosaur,” written with the paleontologist Jack Horner.
admin
Site Admin
 
Posts: 36180
Joined: Thu Aug 01, 2013 5:21 am

Re: U.S. government gave $3.7 million grant to Wuhan lab at

Postby admin » Fri Apr 02, 2021 10:05 pm

China Floats U.S. Military Lab as Possible COVID Origin Point, Urges WHO to Investigate
by Brittany Bernstein
Yahoo News
Wed, March 31, 2021, 10:27 AM

NOTICE: THIS WORK MAY BE PROTECTED BY COPYRIGHT

YOU ARE REQUIRED TO READ THE COPYRIGHT NOTICE AT THIS LINK BEFORE YOU READ THE FOLLOWING WORK, THAT IS AVAILABLE SOLELY FOR PRIVATE STUDY, SCHOLARSHIP OR RESEARCH PURSUANT TO 17 U.S.C. SECTION 107 AND 108. IN THE EVENT THAT THE LIBRARY DETERMINES THAT UNLAWFUL COPYING OF THIS WORK HAS OCCURRED, THE LIBRARY HAS THE RIGHT TO BLOCK THE I.P. ADDRESS AT WHICH THE UNLAWFUL COPYING APPEARED TO HAVE OCCURRED. THANK YOU FOR RESPECTING THE RIGHTS OF COPYRIGHT OWNERS.


China on Wednesday urged the World Health Organization to investigate whether COVID-19 first originated in a U.S. military laboratory after the agency’s director called for a deeper probe into whether the virus had escaped from a Chinese lab.

A WHO-led team that visited China earlier this year to investigate the coronavirus pandemic’s origins said in a report on Tuesday that it was “extremely unlikely” that the virus had leaked from a Chinese laboratory and recommended no further exploration of that theory.

However, just before the report’s release, WHO Director-General Tedros Adhanom Ghebreyesus said the team’s probe into the potential lab leak was not sufficient and that further investigation was needed. He said he was prepared to send more specialists to explore that possibility, according to the Wall Street Journal.

On Wednesday, Chinese Foreign Ministry spokeswoman Hua Chunying responded to a question about Tedros’ comments by touting the team’s “important conclusion” that the lab leak theory was unlikely.

“They have basically excluded the possibility of a lab incident” in Wuhan, she said.

She also called on the agency to investigate early outbreaks in other countries and encouraged the WHO to investigate a U.S. military laboratory at Fort Detrick, Md.

“As you know relevant study is already done in Wuhan labs, but when will Fort Detrick be open to those experts?” she asked. “If necessary, we hope the U.S. can be as open and candid as China.”

For months Chinese officials have peddled the unfounded theory that the virus may have originated at Fort Detrick, which houses parts of the U.S. biological defense program and other medical research efforts led by the military, without offering any evidence.

Hua would not say whether China would allow scientists to continue to investigate the labs in Wuhan or when it would start the second phase of studies outlined in the WHO-led team’s report.

The WHO-led team was forced to rely on the word of the Chinese scientists participating in the investigation and were not given uninhibited access to the Wuhan Institute of Virology, where many public health experts believe the virus may have originated.

The WHO report also contradicted U.S. intelligence claims about the safety protocols at the WIV. The report claims the lab was “well run” but State Department cables from 2018 reveal that diplomats who visited the facility had concerns that proper safety measures were not being observed. The report also suggests that no researchers at the lab came down with COVID but the State department announced in January that researchers reported flu-like symptoms in the fall, months before Chinese authorities acknowledged the COVID outbreak.

WIV staff also deleted a genome database that contained information about which viruses were being studied at the lab.


Dr. Robert Redfield, the former director of the US Centers for Disease Control and Prevention, said last week that he believes the coronavirus originated inside a lab in Wuhan and “escaped,” and was potentially spreading as early as September 2019.

“If I was to guess, this virus started transmitting somewhere in September, October in Wuhan,” the virologist told CNN in a clip that aired Friday. “That’s my own feelings. And only opinion. I’m allowed to have opinions now.”

Redfield said he is “of the point of view that I still think the most likely aetiology of this pathogen in Wuhan was from a laboratory, escaped.”

“The other people don’t believe that,” said Redfield, who led the CDC under former President Donald Trump. “That’s fine. Science will eventually figure it out. It’s not unusual for respiratory pathogens that are being worked on in a laboratory to infect the laboratory worker.”

The WHO-led team’s report also notes that it is possible the pandemic began outside Wuhan, or China, as the team found little evidence of substantial spread in Wuhan before December 2019, while the virus had been found in individuals in Italy and Brazil in late November. However, scientists have said it is possible the virus was spreading undetected in Wuhan and the surrounding areas for weeks or months before gaining attention.

“The current thinking is that we are still working with the start in and around Wuhan and working backwards on how it came here,” said Peter Ben Embarek, the head of the WHO team. “It is perfectly possible you would have sporadic cases in and around Wuhan before December, November, even October 2019…That earlier move of the virus outside of the area could potentially be explained that way.”
admin
Site Admin
 
Posts: 36180
Joined: Thu Aug 01, 2013 5:21 am

Re: U.S. government gave $3.7 million grant to Wuhan lab at

Postby admin » Fri Apr 02, 2021 10:44 pm

OPEN LETTER: Call for a Full and Unrestricted International Forensic Investigation into the Origins of COVID-19
March 4, 2021

1. Introduction

Finding the origins of SARS-CoV-2 is critically important to both better addressing the current pandemic and reducing the risks of future ones. Unfortunately, well over a year after the initial outbreak the origins of the pandemic remain unknown.

As scientists, social scientists, and science communicators who have been independently and collectively looking into the origins of the COVID-19 pandemic, we believe it essential that all hypotheses about the origins of the pandemic be thoroughly examined and full access to all necessary resources be provided without regard to political or other sensitivities.

Based on our analysis, and as confirmed by the global study convened by the World Health Organization (WHO) and Chinese authorities, there is as yet no evidence demonstrating a fully natural origin of this virus. The zoonosis hypothesis, largely based on patterns of previous zoonosis events, is only one of a number of possible SARS-CoV-2 origins, alongside the research-related accident hypothesis.

Although the “collaborative” process of discovery mandated by the World Health Assembly in May 2020 was meant to enable a full examination of the origins of the pandemic, we believe that structural limitations built into this endeavor make it all but impossible for the WHO-convened mission to realize this aspiration.

In particular, we wish to raise public awareness of the fact that half of the joint team convened under that process is made of Chinese citizens whose scientific independence may be limited, that international members of the joint team had to rely on information the Chinese authorities chose to share with them, and that any joint team report must be approved by both the Chinese and international members of the joint team.

We have therefore reached the conclusion that the joint team did not have the mandate, the independence, or the necessary accesses to carry out a full and unrestricted investigation into all the relevant SARS-CoV-2 origin hypotheses - whether natural spillover or laboratory/research-related incident.

Because the joint team investigation falls short of the mark, we believe it essential for the international community to outline how a full and unrestricted investigation could be organized. Such an investigation would need to:


• Be carried out by a truly independent team with no unresolved conflicts of interest and no full or partial control by any specific agenda or country.
• Be multidisciplinary by including epidemiologists, virologists, wildlife experts, public health specialists, forensic investigators, biosafety and biosecurity experts, etc.
• Include several individuals with Chinese-language skills and with an understanding of Chinese culture, who can help to interpret behaviors during the original events and also help decode the dynamic during the investigation itself.
• Start its study by considering all possible scenarios for each pathway. These should include:
o A pure zoonosis event with/without intermediate host;
o Infection at a sampling site of a lab employee or of some accompanying non-lab personnel;
o Infection during transport of collected animals and/or samples;
o Lab Acquired Infection (LAI) in one of the laboratories in Wuhan;
o Lab-escape without LAI, for instance via waste handling or animals that escaped or were disposed of inappropriately.
• Follow a common forensic investigation approach, based on:
o Traditional rigorous on-the-ground investigation;
o Desk-based analyst work to make sense of the elements collected;
o Open-source intelligence to help gather additional information;
o A review of previous zoonosis events and lab-related accidents, from which technical and institutional insights may be gained.
• Have full or significant access to all sites, records, samples, and personnel of interest, including:
o Key Wuhan markets;
o All laboratories and institutions, Chinese or international, known to have worked on coronaviruses or shared facilities or equipment with groups that worked on coronaviruses;
o Hospital records from fall 2019 of early or suspect patients, including interviews with patients or contacts;
o Important pathogen sampling sites, such as the Mojiang mine;
o Current and past personnel, such as employees of the labs in 2019 and people present on specific sampling sites.
• Have full access to all relevant records of the labs and institutions involved in coronavirus research, including:
o Environmental reports;
o Inspection reports;
o Maintenance logs;
o Lab experiment logs;
o Raw sequence reads;
o Records of shipments of samples;
o Specimen destruction records;
o Personnel logs;
o Incident reports;
o Animal breeding records;
o Sampling trip records, including the 2013 Mojiang sampling trip;
o Key databases of pathogens, samples, and isolates, including those taken offline.
• Have full access to granular data, preferably directly from the source and in its raw form, not summarized data. This data can be anonymized if necessary; there should be no legal reason to limit access.
• Have full access to market samples, environmental samples, hospital samples and any potential samples such as waste waters and blood banks with full permission to perform independent sequencing or other testing.
• Have full access to the Chinese CDC case records and related primary hospital and/or clinic records.
• Have full access to other Chinese case databases describing pneumonia cases.
• Be able to conduct confidential interviews, including of early cases and their relatives and past and present personnel associated with the sites or institutions of interest such as markets, hospitals, sampling sites, and laboratories.
• Deploy a secure reporting channel for people to confidentially contribute information, wherever they are based, without fear of punishment or retribution.

4. Conclusion and Next Steps

We recognize that as an international agency that must rely on the collaboration of its member states, the World Health Organization is limited in what it can achieve in this type of investigation. It is not our intention to undermine the WHO, which is working under challenging circumstances at a time of tremendous global need.

Although the joint team investigation was a significant opportunity for the international community to gain some limited and highly curated information, it has unfortunately proven opaque and restrictive, greatly compromising the scientific validity of the investigation.

With more than two million deaths, more than a hundred million infected by COVID-19 worldwide, and a massive global disruption impacting some of the world’s most vulnerable populations, we cannot afford an investigation into the origins of the pandemic that is anything less than absolutely thorough and credible. If we fail to fully and courageously examine the origins of this pandemic, we risk being unprepared for a potentially worse pandemic in the future.

Because we believe the joint team process and efforts to date do not constitute a thorough, credible, and transparent investigation, we call on the international community to put in place a structure and process that does.

Signatories:

• Colin D Butler, Honorary Professor, National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia (ORCID 0000-0002-2942- 5294)
• Bruno Canard, DR CNRS, molecular virologist, Aix Marseille University, France, (ORCID 0000-0003-4924-1991)
• Henri Cap, PhD, zoologist, Museum of Natural History, Toulouse, France
• Y. A. Chan, Postdoctoral Fellow, Broad Institute of MIT & Harvard, Cambridge, USA (ORCID 0000-0002-0731-637X).
• Jean-Michel Claverie, Emeritus Professor of Medicine, virologist, Aix-Marseille University, France, ( ORCID 0000-0003-1424-0315)
• Fabien Colombo, PhD Candidate, Communication and sociology of science, MICA, Université Bordeaux Montaigne, France.
• Virginie Courtier, Evolutionary geneticist, Institut Jacques Monod, CNRS, France (ORCID 0000-0002-9297-9230).
• Francisco A. de Ribera, Industrial Engineer, MBA, MSc(Res), Data scientist, Madrid, Spain (ORCID0000-0003-4419-636X)
• Etienne Decroly, DR CNRS, molecular virologist, Aix Marseille University, France, (ORCID 0000-0002-6046-024X)
• Rodolphe de Maistre, MSc engineering, MBA, ex auditor IHEDN, France (ORCID 0000- 0002-3433-2420)
• Gilles Demaneuf, Engineering (ECP), Data Scientist at BNZ, Auckland, NZ, (ORCID: 0000-0001-7277-9533)(Co-Organizer)
• Richard H. Ebright, Professor of Chemistry and Chemical Biology, Rutgers University, USA
• André Goffinet, MD, PhD, Emeritus Professor, University of Louvain Med Sch, Belgium
• François Graner, biophysicist, Research Director, CNRS and Université de Paris, France, (ORCID 0000-0002-4766-3579)
• José Halloy, Professor of Physics, Biophysics and Sustainability, Université de Paris, France, (ORCID 0000-0003-1555-2484)
• Milton Leitenberg, Senior Research Associate, School of Public Affairs, University of Maryland, USA
• Filippa Lentzos, Senior Lecturer in Science & International Security, King’s College London, United Kingdom (ORCID 0000-0001-6427-4025)
• Rosemary McFarlane, PhD BVSc, Assistant Professor of Public Health, University of Canberra, Australia (ORCID 0000-0001-8859-3776)
• Jamie Metzl, Senior Fellow, Atlantic Council, USA (Co-Organizer)
• Dominique Morello, Biologist, DR CNRS and Museum of Natural History, Toulouse, France
• Nikolai Petrovsky, Professor of Medicine, College of Medicine and Public Health, Flinders University, Australia
• Steven Quay, MD, PhD, Formerly Asst. Professor, Department of Pathology, Stanford University School of Medicine, USA (ORCID 0000-0002-0363-7651)
• Monali C. Rahalkar, Scientist ‘D’, Agharkar Research Institute, Pune, India
• Rossana Segreto, PhD, Department of Microbiology, University of Innsbruck, Austria (ORCID 0000-0002-2566-7042)
• Günter Theißen, Dr. rer. nat., Professor of Genetics, Matthias Schleiden Institute, Friedrich Schiller University Jena, Germany, (ORCID 0000-0003-4854-8692)
• Jacques van Helden, Professor of bioinformatics, Aix-Marseille University, France, (ORCID 0000-0002-8799-8584
admin
Site Admin
 
Posts: 36180
Joined: Thu Aug 01, 2013 5:21 am

Re: U.S. government gave $3.7 million grant to Wuhan lab at

Postby admin » Tue Apr 06, 2021 10:16 pm

World’s Poorest Nations Face Setback as India Suspends Vaccine Exports Amid Fight over Patent Rights
by Amy Goodman
Democracy Now
APRIL 05, 2021

GUESTS
Achal Prabhala: coordinator of the AccessIBSA project, which campaigns for access to medicines in India, Brazil and South Africa.
Leena Menghaney: Indian lawyer who has worked for two decades on pharmaceutical law and policy and heads Médecins Sans Frontières’s access campaign in India.
LINKS
"The world's poorest countries are at India's mercy for vaccines. It's unsustainable"

We look at the urgent push to ensure equal access to COVID-19 vaccines for all nations, rich and poor, and growing calls for Big Pharma to waive their patent rights, as COVID-19 cases soar in India and the Modi government has suspended exports of coronavirus vaccines to many of the world’s poorest countries that depend on AstraZeneca vaccines it produces. “These are not India’s vaccines,” says Achal Prabhala, coordinator of the AccessIBSA project, which campaigns for equitable access to medicines. “The number of vaccine doses that have gone out to a third of humanity — 91 poor countries — is 18 million doses, or just enough to cover about 1% of the populations of these countries if they’ve even got vaccines, which some have not,” Prabhala notes. Leena Menghaney, an Indian lawyer who heads Médecins Sans Frontières’s access campaign in India, links the supply shortage to Oxford University’s decision to sign an exclusive deal with the Serum Institute in India rather than contracting several manufacturers to produce the vaccine. “The monopoly is going to cost us,” Menghaney says.

Transcript

This is a rush transcript. Copy may not be in its final form.

AMY GOODMAN: We begin today’s show with the urgent push to ensure equal access to COVID-19 vaccines for all nations, rich and poor, and growing calls for Big Pharma to waive their patent rights. As Christians around the world marked Easter Sunday, Italy moved up midnight Masses to meet a 10 p.m. curfew amidst a spike in COVID cases. And Pope Francis used his Easter Mass address at St. Peter’s Basilica in the Vatican to warn against vaccine nationalism.

POPE FRANCIS: [translated] In the spirit of an internationalism of vaccines, I urge the entire international community to a common commitment to overcome the delays in their distribution and to promote their distribution especially in the poorest countries.

AMY GOODMAN: According to Oxfam, rich countries, with just 13% of the world’s population, have bought up more than 60% of vaccines even before their production. This comes as COVAX, the United Nations initiative to bring mass vaccination to poorer countries, has placed orders for more than 2 billion shots, but most of them won’t come until the second half of this year.

Meanwhile, deliveries from the world’s biggest coronavirus vaccine manufacturer in India have been delayed as COVID-19 cases soar to record highs in India and the Modi government has suspended vaccine exports. With more than 12.6 million confirmed coronavirus cases, India has the world’s third-highest caseload, after the United States and Brazil.

On Sunday, the head of the public-private GAVI Alliance, which works to provide vaccines to the developing world and is backed by the United Nations and the Gates Foundation, addressed the delay during an interview on CBS’s Face the Nation. This is Seth Berkley.

DR. SETH BERKLEY: So, India is, by volume, the largest supplier of vaccines for the developing world. And because of the new wave of outbreaks in India right now, the Indian government has stepped up their vaccination programs. And that has meant that they’ve required more doses, which means that they’ve made less doses available for the rest of the world. We had expected, in March and April, about 90 million doses, and we suspect we’ll get much, much less than that. And that is a problem.

But we’re in a race, because we also see wealthy countries beginning to cover much of their population, and our hope is that they will begin to make their vaccines available to the rest of the world, including ones that they may not use. For example, the U.S. not only has Moderna, Pfizer and J&J, but they also have vaccines from Novavax and, of course, from AstraZeneca. Those could be made available, and they would make a big difference in terms of the supply for the world.

AMY GOODMAN: Well, our next guests write about this in a new piece for The Guardian headlined “The world’s poorest countries are at India’s mercy for vaccines. It’s unsustainable.” In it, they note that as the U.K. saw a delay in doses from India, quote, “a far more chilling reality was unfolding: about a third of all humanity, living in the poorest countries, found out that they will get almost no coronavirus vaccines in the near future because of India’s urgent need to vaccinate its own massive population.

For more, we go to India, where we’re joined in Bangalore by Achal Prabhala. He is the coordinator of the AccessIBSA project, which campaigns for access to medicines in India, Brazil and South Africa. And in Delhi, Leena Menghaney is with us, an Indian lawyer who has worked for two decades on pharmaceutical law and policy. She is head of the Médecins Sans Frontières — that’s Doctors Without Borders — access campaign in India.

We welcome you both to Democracy Now! Achal Prabhala, it’s great to have you back. You co-authored this piece. Elaborate further on what is taking place, this as we hear Pope Francis’s address demanding the wealthy countries ensure that the world gets these vaccines, especially the poorest countries.

ACHAL PRABHALA: Thank you.

What we’re seeing now is a failure that was foretold over a year ago, when vaccine manufacturing and vaccine research just began. What’s happening today is a set of cumulative failures over the last year, many of which were predicted, many of which could have been avoided.

Of the vaccines available in the world, there are vaccines from Pfizer and Moderna which are simply not available outside rich countries. AstraZeneca is one of the few companies that has made its vaccine a little more available, primarily by signing an agreement with the largest vaccine manufacturer in the world, who happens to be located in India. Now, the problem is that what they signed over were the rights to supply vaccines to 92 poor countries around the world, including India, essentially to one vaccine manufacturer, with very, very few backups. What that’s meant is that you have these 92 countries that are dependent upon one company that operates on Indian soil.

Now, by its share of population, India should get about 35% of these vaccines. What’s happening instead is that the Indian government is acquiring far more of those vaccines than 35%. At this moment and for the next couple of months, it’s going to be closer to 100%. The problem with this is that these are not India’s vaccines. These vaccines were always meant, contractually, for about half of humanity, including India. Now, they’re not getting there. Seth Berkley, the head of the COVAX initiative, which promised to provide a pipeline of vaccines to these poor countries last year, has said that he hoped to have 100 million doses out. The reality is so much worse, because what he has out are 28 million vaccines, 10 million of which went right back to India. So the number of vaccine doses that have gone out to a third of humanity — 91 poor countries — is 18 million doses, or just enough to cover about 1% of the populations of these countries if they’ve even got vaccines, which some have not.

AMY GOODMAN: [inaudible] Leena Menghaney about the consequence of the contract between Oxford and AstraZeneca with the Serum Institute in India, just to explain for people to understand what is taking place and the role of these large pharmaceutical companies.

LEENA MENGHANEY: Yeah. I’ve worked in pharmaceuticals and biopharmaceuticals for 20 years. And the rule is, you have to have at least three suppliers. If you look at India itself, it has many manufacturing sites and many manufacturers. The decision to go and have an exclusive deal with Serum Institute is going to cost lives, because that’s exactly where it all started, with Oxford granting exclusive rights to AstraZeneca, and AstraZeneca choosing to tie up with one single manufacturer.

We all know that India is the pharmacy of the developing world. They could produce more, and they should have transferred technology and the rights to produce these vaccines to more than one company. The monopoly is going to cost us. We need to have scaled up not with just Serum Institute, but a large number of other manufacturers in India.

So, now India is in this difficult position where it has to vaccinate its own people at a faster and faster pace to beat the epidemic, and then, at the same time, actually ensure that these vaccines go to the developing world. We’re at a very difficult point in India’s, you know, policymakers’ — I wouldn’t want to be in their shoes today.

AMY GOODMAN: Achal, you write in the piece with Leena, “The billions of AstraZeneca doses being produced by the Serum Institute in India are not for rich countries — and, in fact, not even for India alone: they are for all 92 of the poorest countries in the world. … [T]he bulk of India’s vaccination goals will be met by just one supplier, which faces the impossible choice of either letting down the other 91 countries depending on it, or offending its own government.” Can you talk more about this and the gross vaccine inequities we’re seeing across the globe?

ACHAL PRABHALA: Absolutely. One of the interesting things about this is how it begins. Oxford University has a research laboratory called the Jenner Institute, which shows early promise on research for a coronavirus vaccine. This is at exactly this time last year, in about March. They suggest, in public statements, that they would like to have as many manufacturers around the world make the vaccine. It’s not necessarily nonprofit or technically open source, but they have this idea of a world in which anyone can make their vaccine. The Gates Foundation steps in, advises the Jenner Institute to go with a pharmaceutical company. One month later, they sign an exclusive contract with AstraZeneca, a U.K.-based multinational pharmaceutical corporation. AstraZeneca then licenses a large number of doses to the Serum Institute in India; they license a firm in South Korea — both of which are now producing vaccines. But what they do is that they transfer one concentration of monopoly power to another manufacturer with another kind of monopoly power, the monopoly power to supply half the world’s population, including India, with a number of vaccine doses that is simply not enough.

One of the funny things about this is that it’s as though everybody involved, from the Gates Foundation to AstraZeneca and, unfortunately, including the government of India — it’s as though they suddenly realized how many people live in India. Our population is not a secret. We have 1.3 billion people. We’ve always known that these people would require vaccines. And yet it seems to have taken the government of India until about two months ago to discover that we would have to ramp up our vaccination program, at which point they decided, through this result of colossal bad planning and cumulatively bad decisions, to essentially usurp vaccines that were meant for other poor countries, who do not have the kind of vaccine manufacturing capacity India does. And because they’re being made within Indian sovereign territory, they are actually able to do that, to the detriment of countries like Ghana or Nigeria, who have received enough doses to inoculate 1% of their population, will now have to wait at least until July this year, but possibly much longer, because India’s vaccination needs, as well, will continue to be met by this one company, where all the vaccines — where all the vaccine doses are concentrated for all of these countries for the next several months.

AMY GOODMAN: Leena, can you talk about the need, the — what you’re calling for, with the People’s Vaccine initiative around the world, as well, calling for this, as well as countries like India and South Africa, calling for pharmaceutical — the WTO and the U.S. to support the waiving of patents by pharmaceutical companies?

LEENA MENGHANEY: Yeah. So, this proposal is quite interesting. It shifts power from pharmaceutical corporations to government. And what it really says is that we learn from experience. In HIV/AIDS, we had to overcome patent barriers country by country, drug by drug. And instead, what they have proposed is that we waive our intellectual property automatically in one go, you know, saving a lot of time along the way in producing not just vaccines, but medicines and other medical products.

So, in a nutshell, what India and South Africa proposed and asked the world to support them on was that we don’t have to do this the hard way. We don’t have to lose lives like we did in the HIV/AIDS epidemic. We don’t have to overcome patents country by country. And what we do is an automatic waiving of intellectual property monopolies. And that actually could result in fastening of, you know, production in many new regions and countries who are investing in sort of coming into making pharmaceuticals and vaccines.

AMY GOODMAN: And, Achal Prabhala, can you also elaborate on this? There’s been a big push. We just spoke with the former foreign secretary of Brazil. And, of course, COVID is just exploding there. And he also expressed grave disappointment in the Biden administration for not supporting the call at the WTO to waive the intellectual rights of these corporations during the pandemic.

ACHAL PRABHALA: There’s no choice. They must. If they wish to have a solution that works not only for the rest of the world, poor countries, but also for them, eventually, in their own selfish interests, they must find a way to waive or suspend pharmaceutical monopolies in the pandemic.

Interestingly, one of the things that’s happening at the World Trade Organization is that this AstraZeneca access agreement, that we analyzed, which has turned out to be quite catastrophic, is being held up as the example. We’re criticizing AstraZeneca, but that’s because they’ve actually done something to make access available. Companies like Pfizer and Moderna, and even Johnson & Johnson to a certain extent, have done nothing.

Now, AstraZeneca’s licensing agreement, however much it’s a step up from what Pfizer and Moderna have done, is, in fact, a failure. It’s not working out. It’s inadequate. It needed to have been bigger and better and taken into account the real needs of the real people who live in this world. So, the idea that you can leave it up to pharmaceutical companies to occasionally license their products and to slightly distribute the extreme concentration of power that they have, which is a proposal being actively discussed at the WTO, is foolish. And I hope that the example of how the AstraZeneca agreement has worked out will serve as caution for the fact that nothing other than a dramatic step to suspend pharmaceutical monopolies all over the world will get us out of this pandemic.

AMY GOODMAN: Achal Prabhala, you talk about Oxford University’s original motivations for developing the vaccine, and you talk about motives being thwarted by the Gates Foundation. How?

ACHAL PRABHALA: Oxford University had this idea that since we were in a pandemic that created this global emergency, they must do something that would step out of the norms of the kind of pharmaceutical research they do. What they wanted to have, very clearly expressed by the lead researchers, by Adrian Hill and Sarah Gilbert at that time, was to be able to license as many manufacturers as possible around the world. I don’t think they ever intended to lose money, but they didn’t intend to turn it into the kind of pharmaceutical juggernaut that coronavirus vaccines have become. This was very clearly expressed.

But very quickly, on the advice of the Gates Foundation and a few other parties — the U.K. government was involved — the contract completely changed, and the system of licensing this vaccine was dramatically reversed. They signed an exclusive contract with AstraZeneca, that then further went out and created a handful of these access licenses, of which it’s only truly one that functions and serves for half the world’s population.

It’s a mistake of tragic proportions that I’m not sure every party involved understands. I believe they were working with the best intentions, but they were working without an understanding of the last 20 years of human history. It’s a mistake that should definitely not be repeated, certainly not be held up as a solution, and it’s something that we need to reverse and correct at this moment.

AMY GOODMAN: And finally, you mentioned that while you are very critical of AstraZeneca, that Moderna and Pfizer’s contracts are worse. Explain.

ACHAL PRABHALA: Pfizer and Moderna are running on this model where they believe supplying literally between 15 and 20% of the world, which is the cumulative population of everyone who lives in rich countries, is sufficient. They will not do a thing more than that. Eighty percent of the world or 85% of the world is being left out to dry.

The idea is that they are going to places where they have high-paying customers, usually in the form of governments, from whom they have these huge preorders. Moderna posted revenue of $18 billion this year, so they’re doing well out of this strategy. And their idea is to limit the production of vaccines to the people who can afford them, to safeguard their relatively new technology of a messenger RNA platform that they’ve deployed in this vaccine, to protect that platform against future exploitation, against future commercial use. To the extent that it is democratized and there are more people who can manufacture this around the world, even in the pandemic, I think it threatens their ability to exploit the platform in the future. So the idea is to hold this close, to serve in the pandemic those who can pay, and pay no heed and no mind to anybody who lives outside this tiny handful of countries that they’re currently serving and doing very well for them.

AMY GOODMAN: And as we know from the pandemic, what it has taught us, if nothing else, if one person is sick somewhere, everyone has the potential to be sick. I want to thank you, Achal Prabhala, coordinator of the AccessIBSA object, which stands for India, Brazil, South Africa, and Leena Menghaney, heads up Médecins Sans Frontières, Doctors Without Borders, access campaign in India. We’ll link to your op-ed in The Guardian, “The world’s poorest countries are at India’s mercy for vaccines. It’s unsustainable.”
admin
Site Admin
 
Posts: 36180
Joined: Thu Aug 01, 2013 5:21 am

PreviousNext

Return to Health

Who is online

Users browsing this forum: No registered users and 15 guests